Middle East & Africa In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Technique, Product, Usability, Application, End User, Diagnostic Approach and Geography

Market Snapshot

MIDDLE East & Africa IVD Market_1
Study Period: 2018 - 2026
Base Year: 2020
Market Value (2018): USD 2,286.60 million
Market Value (2024): USD 3,013.94 million

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Middle East & Africa In-Vitro Diagnostics market studied was valued at USD 2,286.60 million in 2018, and is expected to reach USD 3,013.94 million by 2024, with an anticipated CAGR of 4.71%, during the forecast period (2019-2024).

The major driving factors linked to the growth of the IVD industry is high burden of chronic diseases, especially infectious diseases and diabetes, along with cancers, which contribute largely to the demand and rise of IVD. Companies are releasing self testing devices at lower costs in collaboration with governments and non-profit organizations.

The Middle East & Africa region is majorly affected due to the burden of chronic diseases. The prime factor responsible for this rising burden is the lack of proper healthcare system across the African countries and low awareness about the novel disease diagnosis techniques. South Africa has the moat number of HIV infected population and it has been stated by the National Institute of Health that around 5.7 million people in the country were suffering from HIV, during 2016-2017. As per the report published by a Network of Civil Society Organisations (2018), it was sensed that South Africa was experiencing the surge in the NCDs (Non Communicable Diseases), such as heart diseases, stroke, cancer, diabetes, and chronic lung disease. Due to this rise in the chronic diseases, it is believed that the African region will be facing a high demand for diagnostics, as the growing burden is a result of lack of proper diagnosis.

Scope of the Report

In vitro diagnostics is defined as a medical device used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring, or compatibility purposes.

By Technique
Molecular Diagnostics
Self-blood Glucose Testing
Other Techniques
By Product
Other Products
By Usability
Disposable IVD Device
Reusable IVD Device
By Application
Infectious Disease
Autoimmune Disease
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users
By Diagnostic Approach
Point-of-Care Diagnostics
Centralized Laboratory-based Diagnostics
South Africa
Rest of Middle East & Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

Diabetes is Expected to Grow with High CAGR in the Application Segment

Infectious diseases, HIV/AIDS and poverty, have traditionally dominated the African region, but diabetes has become a new priority. The surveys carried out recently by the WHO (World Health Organization) in the African region indicate that up to 15% of adults aged 25 to 64 have diabetes. According to the IDF (International Diabetes Federation) Diabetes Atlas 8th Edition, a projected 15.5 million adults of age 20-79 years were having diabetes in the IDF African region in 2017, accounting for a prevalence of 3.3% across the entire region. The WHO and the IDF estimate that the diabetes population may double over the next 25 years in Africa. This raises massive healthcare concerns, as all African countries are already struggling to cope up with the diabetes burden. However, WHO reports that diabetes in the region is a serious, chronic, and costly disease that is estimated to rise to 23.9 million cases, by 2030. Hence, the rising prevalence of the disease is expected to drive the growth of the concerned segment, over the forecast period.

MIDDLE East & Africa IVD Market_2

Competitive Landscape

The Middle East & Africa In-Vitro Diagnostics market is competitive and consists of several major players. In terms of market share, few of the major players are currently dominate the market in the GCC. Some of the major players of the market are Abbott Laboratories, Danaher Corporation, Sysmex Corp., F. Hoffmann-La Roche AG, and Becton, Dickinson and Company are among others. The companies mostly monitor distribution via their branch office or the distributor operating at the domestic and international levels. The United Arab Emirates and Saudi Arabia are largely medical tourism countries, and as a result, they are the most important locations for many companies in the Middle East & Africa region.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Chronic Diseases

      2. 4.2.2 Increasing Use of Point-of-Care (PoC) Diagnostics

      3. 4.2.3 Increasing Use of Advanced Technologies

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Technique

      1. 5.1.1 Histochemistry

      2. 5.1.2 Molecular Diagnostics

      3. 5.1.3 Hematology

      4. 5.1.4 Self-blood Glucose Testing

      5. 5.1.5 Immunochemistry

      6. 5.1.6 Other Techniques

    2. 5.2 By Product

      1. 5.2.1 Instrument

      2. 5.2.2 Reagent

      3. 5.2.3 Other Products

    3. 5.3 By Usability

      1. 5.3.1 Disposable IVD Device

      2. 5.3.2 Reusable IVD Device

    4. 5.4 By Application

      1. 5.4.1 Infectious Disease

      2. 5.4.2 Diabetes

      3. 5.4.3 Cancer/Oncology

      4. 5.4.4 Cardiology

      5. 5.4.5 Autoimmune Disease

      6. 5.4.6 Other Applications

    5. 5.5 By End User

      1. 5.5.1 Diagnostic Laboratories

      2. 5.5.2 Hospitals and Clinics

      3. 5.5.3 Other End Users

    6. 5.6 By Diagnostic Approach

      1. 5.6.1 Point-of-Care Diagnostics

      2. 5.6.2 Centralized Laboratory-based Diagnostics

    7. 5.7 Geography

      1. 5.7.1 GCC

      2. 5.7.2 South Africa

      3. 5.7.3 Rest of Middle East & Africa


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Danaher Corporation

      3. 6.1.3 F. Hoffmann-La Roche AG

      4. 6.1.4 Becton, Dickinson and Company

      5. 6.1.5 BioMerieux SA

      6. 6.1.6 Siemens Healthineers

      7. 6.1.7 Thermo Fischer Scientific Inc.

      8. 6.1.8 Qiagen NV

      9. 6.1.9 Seegene Inc.

      10. 6.1.10 Sysmex Corp.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA In-Vitro Diagnostics Market market is studied from 2018 - 2026.

The MEA In-Vitro Diagnostics Market is valued at 4.71% in 2018.

The MEA In-Vitro Diagnostics Market is valued at USD 2,286.60 million in 2026.

Abbott Laboratories, Danaher Corporation, Sysmex Corp., F. Hoffmann-La Roche AG, Becton, Dickinson and Company are the major companies operating in MEA In-Vitro Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!